eISSN 2329-0358

Logo



Welcome to the Annals of Transplantation

Annals of Transplantation is one of the fast-developing journals open to all scientists and fields of transplant medicine and related research. The journal is published quarterly and provides extensive coverage of the most important advances in transplantation.
Using an electronic on-line submission and peer review tracking system, Annals of Transplantation is committed to rapid review and publication. The average time... read more


Published: 2017-02-28

Living Donor Liver Transplantation for Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Experience of a Single Center

Cheng-Chih Chang, Ying-Ju Chen, Tzu-Hao Huang, Chun-Han Chen, Fang-Ying Kuo, Hock-Liew Eng, Chee-Chien Yong, Yueh-Wei Liu, Ting-Lung Lin, Wei-Feng Li, Yu-Hung Lin, Chih-Che Lin, Chih-Chi Wang, Chao-Long Chen

(Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan)

Ann Transplant 2017; 22:115-120

DOI: 10.12659/AOT.900779


BACKGROUND: Because the outcome of liver transplantation for cholangiocarcinoma is often poor, cholangiocarcinoma is a contraindication for liver transplantation in most centers. Combined hepatocellular carcinoma and cholangiocarcinoma is a rare type of primary hepatic malignancy containing features of hepatocellular carcinoma and cholangiocarcinoma. Diagnosing combined hepatocellular carcinoma and cholangiocarcinoma pre-operatively is difficult. Because of sparse research presentations worldwide, we report our experience with living donor liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma.
MATERIAL AND METHODS: A total of 710 patients underwent living donor liver transplantation at our institution from April 2006 to June 2014; 377 of them received transplantation because of hepatocellular carcinoma with University of California San Francisco (UCSF) staging criteria fulfilled pre-operatively. Eleven patients (2.92%) were diagnosed with combined hepatocellular carcinoma and cholangiocarcinoma confirmed pathologically from explant livers; we reviewed these cases retrospectively. Long-term survival was compared between patients diagnosed with combined hepatocellular carcinoma and cholangiocarcinoma and patients diagnosed with hepatocellular carcinoma.
RESULTS: The mean age of the patients in our series was 60.2 years, and the median follow-up period was 23.9 months. Four patients were diagnosed with a recurrence during the follow-up period, including one intra-hepatic and three extra-hepatic recurrences. Four patients died due to tumor recurrence. Except for patients with advanced-stage cancer, disease-free survival of patients with combined hepatocellular carcinoma and cholangiocarcinoma compared with that of patients with hepatocellular carcinoma was 80% versus 97.2% in 1 year, and 46.7% versus 92.5% in 3 years (p<0.001), and overall survival was 90% versus 97.2% in 1 year, and 61.7% versus 95.1% in 3 years (p<0.001).
CONCLUSIONS: Outcomes of liver transplantation for patients with combined hepatocellular carcinoma and cholangiocarcinoma were worse than those for patients with hepatocellular carcinoma in this study. Combined hepatocellular carcinoma and cholangiocarcinoma are presumed to be a relative contraindication for liver transplantation.

Keywords: Carcinoma, Hepatocellular, Cholangiocarcinoma, Liver Transplantation



Related Articles (0)

Coming Soon...

Published: 2017-02-24

Clinical Impact of Liver Biopsies in Liver Transplant Recipients


Torsten Voigtländer, Tim A. Alten, Martha M. Kirstein, Frank Lehner, Michael P. Manns, Jerome Schlué, Heiner Wedemeyer, Tim O Lankisch

Ann Transplant 2017; 22:108-114

DOI: 10.12659/AOT.901487

Published: 2017-02-21

Proposal for a New Predictive Model of Short-Term Mortality After Living Donor Liver Transplantation due ...


Hyun Sik Chung, Yu Jung Lee, Yun Sung Jo

Ann Transplant 2017; 22:101-107

DOI: 10.12659/AOT.901771